BIOCON.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:51):

Stats
Šios dienos apimtis	12.84M
Vidutinė apimtis	8.13M
Rinkos kapitalizacija	368.64B
EPS	INR0 ( 2024-02-08 )
Kita pelno data	( INR1.300 ) 2024-05-16
Last Dividend	INR1.500 ( 2023-07-06 )
Next Dividend	INR0 ( N/A )
P/E	30.64
ATR14	INR0.314 (0.10%)

Tūris Koreliacija

Ilgas: -0.43 (neutral)

Trumpas: -0.05 (neutral)

Signal:(68.286) Neutral

Biocon Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APLLTD.NS	0.953
MSUMI.NS	0.946
IMPEXFERRO.NS	0.943
NAVNETEDUL.NS	0.942
LICNFNHGP.NS	0.938
TATACONSUM.NS	0.935
TATACOFFEE.NS	0.933
ICICI500.NS	0.93
ENIL.NS	0.929
ICICINF100.NS	0.929

10 Labiausiai neigiamai susiję koreliacijos
4THDIM.NS	-0.948
JSL.NS	-0.925
LTGILTBEES.NS	-0.908
RAJRILTD.NS	-0.906
ISMTLTD.NS	-0.9
KIRLFER.NS	-0.876
JSLHISAR.NS	-0.869
SUNFLAG.NS	-0.864
OIL.NS	-0.86
DFMFOODS.NS	-0.859

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Biocon Limited Koreliacija - Valiuta/Žaliavos

0.33
( neutral )

0.28
( neutral )

0.49
( neutral )

0.48
( neutral )

-0.14
( neutral )

-0.32
( neutral )

Biocon Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR111.74B
Bruto pelnas:	INR75.11B (67.22 %)
EPS:	INR3.88

FY	2022
Pajamos:	INR111.74B
Bruto pelnas:	INR75.11B (67.22 %)
EPS:	INR3.88

FY	2022
Pajamos:	INR80.25B
Bruto pelnas:	INR53.01B (66.06 %)
EPS:	INR5.44

FY	2021
Pajamos:	INR69.70B
Bruto pelnas:	INR47.60B (68.29 %)
EPS:	INR6.24

Financial Reports:

No articles found.

Biocon Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Biocon Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 6.47 - average (82.41%) | Divividend Growth Potential Score: 2.72 - Decrease likely (45.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0833	2004-07-01
Last Dividend	INR1.500	2023-07-06
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	19	--
Total Paid Out	INR10.21	--
Avg. Dividend % Per Year	0.18%	--
Score	1.84	--
Div. Sustainability Score	6.47
Div.Growth Potential Score	2.72
Div. Directional Score	4.59	--

Next Divdend (Est)
(2024-06-14)

INR1.691 Estimate 3.08 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.84

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.16%
2019	INR0.500	0.16%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0.500	0.14%
2023	INR1.500	0.57%
2024	INR0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
ROHLTD.NS	Dividend Junior	2023-09-15	Sporadic	19	0.20%
LAURUSLABS.NS	Dividend Knight	2023-05-10	Semi-Annually	8	0.35%
FOSECOIND.NS	Dividend Knight	2023-05-17	Annually	22	0.68%
APOLLO.NS	Dividend Junior	2023-09-22	Annually	7	0.79%
TCI.NS	Dividend Junior	2023-07-25	Semi-Annually	23	0.70%
OBEROIRLTY.NS	Dividend Junior	2023-06-21	Sporadic	14	0.19%
INFOBEAN.NS	Dividend Junior	2023-07-21	Annually	7	0.37%
CONCOR.NS	Dividend Knight	2023-09-18	Semi-Annually	23	0.89%
SCI.NS	Dividend Junior	2023-09-01	Sporadic	22	0.25%
MALLCOM.NS	Dividend Junior	2023-09-04	Annually	3	0.20%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0845	1.500	8.31	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0216	1.200	9.28	10.00	[0 - 0.3]
returnOnEquityTTM	0.0636	1.500	-0.404	-0.606	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.104	0.800	9.48	7.59	[1 - 3]
quickRatioTTM	0.627	0.800	-1.018	-0.814	[0.8 - 2.5]
cashRatioTTM	0.135	1.500	-0.359	-0.539	[0.2 - 2]
debtRatioTTM	0.291	-1.500	5.16	-7.74	[0 - 0.6]
interestCoverageTTM	2.65	1.000	-0.128	-0.128	[3 - 30]
operatingCashFlowPerShareTTM	20.50	2.00	3.17	6.33	[0 - 30]
freeCashFlowPerShareTTM	20.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.817	-1.500	6.73	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.662	1.000	2.29	2.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.186	1.000	8.28	8.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.153	1.000	-0.264	-0.264	[0.2 - 2]
assetTurnoverTTM	0.256	0.800	-1.628	-1.302	[0.5 - 2]
Total Score				6.47

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	30.65	1.000	7.01	0	[1 - 100]
returnOnEquityTTM	0.0636	2.50	-0.260	-0.606	[0.1 - 1.5]
freeCashFlowPerShareTTM	20.50	2.00	3.17	10.00	[0 - 30]
dividendYielPercentageTTM	0.490	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	20.50	2.00	3.17	6.33	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-24.21	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.173	1.000	8.17	0	[0.1 - 0.5]
Total Score				2.72

Biocon Limited

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.